JHL Biotech, a biopharmaceutical startup, has named Ellis Chu as its new Chief Financial Officer, effective May 2018, it was reported yesterday.

Chu most recently served as a Managing Director and the Head of Greater China at Ion Pacific. Prior to Ion Pacific, Ellis worked in investment banking, including as Head of China Mergers & Acquisitions at Bank of America Merrill Lynch. He also held senior investment banking positions at Citigroup, Nomura and Lehman Brothers.

Racho Jordanov, JHL Biotech's Co-Chairman and CEO, said, 'We are delighted to have someone of Ellis Chu's caliber join JHL's management team at this critical point in our company's development. Ellis's prior experience will be an asset as business development and the capital markets become increasingly important to JHL.'